Castration-resistant prostate cancer: From new pathophysiology to new treatment

European Urology

Volumn 65, Issue 2, 2014, Pages 289-299

  Sridhar, Srikala S ^a   Freedland, Stephen J ^b   Gleave, Martin E ^c   Higano, Celestia ^d   Mulders, Peter ^e   Parker, Chris ^f   Sartor, Oliver ^g   Saad, Fred ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Seattle Cancer Center Alliance   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Abiraterone; Cabazitaxel; CRPC; Enzalutamide; Novel treatments; Radium 223; Sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; ARN 509; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DOCETAXEL; ENZALUTAMIDE; GALETERONE; IPILIMUMAB; ORTERONEL; PROGRAMMED DEATH 1 RECEPTOR; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; ASYMPTOMATIC DISEASE; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG APPROVAL; HUMAN; META ANALYSIS; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REFERENCE DATABASE; REVIEW; SYSTEMATIC REVIEW;

ABIRATERONE; CABAZITAXEL; CRPC; ENZALUTAMIDE; NOVEL TREATMENTS; RADIUM-223; SIPULEUCEL T;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84891835267     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.008     Document Type: Review

References (70)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. M.M. Center, A. Jemal, and J. Lortet-Tieulent et al. International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
3. C. Huggins Effect of orchiectomy and irradiation on cancer of the prostate Ann Surg 115 1942 1192 1200
4. J.L. Mohler Castration-recurrent prostate cancer is not androgen-independent Adv Exp Med Biol 617 2008 223 234
5. J.L. Mohler A role for the androgen-receptor in clinically localized and advanced prostate cancer Best Pract Res Clin Endocrinol Metab 22 2008 357 372
6. F. Azzouni, and J. Mohler Biology of castration-recurrent prostate cancer Urol Clin North Am 39 2012 435 452
7. Y. Chen, N.J. Clegg, and H.I. Scher Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol 10 2009 981 991
8. G.A. Potter, S.E. Barrie, M. Jarman, and M.G. Rowlands Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer J Med Chem 38 1995 2463 2471
9. S.E. Barrie, B.P. Haynes, and G.A. Potter et al. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors J Steroid Biochem Mol Biol 60 1997 347 351
10. M. Jarman, S.E. Barrie, and J.M. Llera The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors J Med Chem 41 1998 5375 5381
11. G. Attard, A.H. Reid, and T.A. Yap et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
12. J.S. de Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
13. C.J. Ryan, S. Shah, and E. Efstathiou et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response Clin Cancer Res 17 2011 4854 4861
14. C.J. Logothetis, E. Basch, and A. Molina et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
15. C.J. Ryan, M.R. Smith, and J.S. de Bono et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
16. D. Rathkopf, M. Smith, and J. De Bono et al. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy [abstract 5] J Clin Oncol 31 Suppl 6 2013
17. M.E. Taplin, R.B. Montgomery, and C. Logothetis et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study [abstract 4521] J Clin Oncol 30 Suppl 2012
18. T. Kaku, T. Hitaka, and A. Ojida et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorg Med Chem 19 2011 6383 6399
19. T. Hara, J. Kouno, and T. Kaku et al. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats J Steroid Biochem Mol Biol 134 2013 80 91
20. D.P. Petrylak, J.G. Gandhi, and W.R. Clark et al. A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): updated phase II results [abstract 59] J Clin Oncol 31 Suppl 6 2013
21. R. Dreicer, D. Agus, and J. Bellmunt et al. A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy [abstract TPS4693] J Clin Oncol 30 Suppl 2012
22. H.I. Scher, T.M. Beer, and C.S. Higano et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
23. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
24. E.S. Baskin-Bey, N.D. Shore, K. Barber, T. Ouatas, and A. Heidenreich TERRAIN: a randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC) [abstract TPS4698] J Clin Oncol 30 Suppl 2012
25. R.B. Montgomery, A. Joshua, and A.L. Hannah et al. A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer [abstract TPS4695] J Clin Oncol 30 Suppl 2012
26. N.J. Clegg, J. Wongvipat, and J.D. Joseph et al. ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 72 2012 1494 1503
27. D. Rathkopf, N.D. Shore, and E.S. Antonarakis et al. A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC) [abstract TPS4697] J Clin Oncol 30 Suppl 2012
28. R.D. Bruno, T.S. Vasaitis, and L.K. Gediya et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model Steroids 76 2011 1268 1279
29. R.B. Montgomery, M.A. Eisenberger, and M. Rettig et al. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC) [abstract 4665] J Clin Oncol 30 Suppl 2012
30. V. Harris, K. Lloyd, S. Forsey, P. Rogers, M. Roche, and C. Parker A population-based study of prostate cancer chemotherapy Clin Oncol 23 2011 706 708
31. I.F. Tannock, D. Osoba, and M.R. Stockler et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
32. I.F. Tannock, R. de Wit, and W.R. Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
33. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
34. S.N. Chin, L. Wang, M. Moore, and S.S. Sridhar A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital Curr Oncol 17 2010 24 29
35. A.C. Mita, L.J. Denis, and E.K. Rowinsky et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
36. J.S. de Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
37. J. De Bono, S. Oudard, and M. Ozguroglu et al. A subgr oup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) [abstract 4526] J Clin Oncol 29 Suppl 2011
38. M. Ozguroglu, S. Oudard, and A.O. Sartor et al. Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel [abstract15131] J Clin Oncol 29 Suppl 2011
39. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
40. E.J. Small, N. Sacks, and J. Nemunaitis et al. Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer Clin Cancer Res 13 2007 3883 3891
41. C.S. Higano, P.F. Schellhammer, and E.J. Small et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
42. R.S. DiPaola, M. Plante, and H. Kaufman et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer J Transl Med 4 2006 1
43. P.W. Kantoff, T.J. Schuetz, and B.A. Blumenstein et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
44. S.F. Slovin, C.S. Higano, and O. Hamid et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
45. Y. Agata, A. Kawasaki, and H. Nishimura et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int Immunol 8 1996 765 772
46. S.L. Topalian, F.S. Hodi, and J.R. Brahmer et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
47. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
48. K. Liepe Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer Curr Opin Investig Drugs 10 2009 1346 1358
49. C. Parker, D. Heinrich, and J.M. O'Sullivan et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 8] J Clin Oncol 30 Suppl 5 2012
50. W.K. Kelly, S. Halabi, and M. Carducci et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 2012 1534 1540
51. D.P. Petrylak, K. Fizazi, and C.N. Sternberg et al. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial [abstract LBA24] Paper presented at: Meeting of the European Society of Medical Oncology September 28-October 2, 2012; Vienna, Austria 2012
52. I.F. Tannock, K. Fizazi, and S. Ivanov et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial Lancet Oncol 14 2013 760 768
53. J.C. Araujo, G.C. Trudel, and F. Saad et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial [abstract LBA8] J Clin Oncol 31 Suppl 6 2013
54. E.J. Small, T. Demkow, and W.R. Gerritsen et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract 7] J Clin Oncol Suppl 2009
55. H.I. Scher, X. Jia, and K. Chi et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer J Clin Oncol 29 2011 2191 2198
56. D. Quinn, C.M. Tangen, and M. Hussain et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC) [abstract 4511] J Clin Oncol 30 Suppl 2012
57. K.S. Fizazi, C.S. Higano, and J.B. Nelson et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer J Clin Oncol 31 2013 1740 1747
58. M.D. Michaelson, S. Oudard, and Y. Ou et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract 4515] J Clin Oncol 29 Suppl 2011
59. F.M. Yakes, J. Chen, and J. Tan et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2011 2298 2308
60. D.C. Smith, M.R. Smith, and C. Sweeney et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419
61. A.J. Armstrong, M. Haggman, and W.M. Stadler et al. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial [abstract 4550] J Clin Oncol 30 Suppl 2012
62. K.N. Chi, S.J. Hotte, and E.Y. Yu et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 4247 4254
63. J. Mezynski, C. Pezaro, and D. Bianchini et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947
64. R.J. van Soest, M.E. van Royen, and E.S. de Morree et al. Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide. Potential mechanisms for cross-resistance in castration-resistant prostate cancer (CRPC) [abstract 5064] J Clin Oncol 31 Suppl 2013
65. E.S. Antonarakis, A.S. Kibel, and G. Adams et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results [abstract 5016] J Clin Oncol 31 Suppl 2013
66. D. Mukherji, C.J. Pezaro, A. Shamseddine, and J.S. De Bono New treatment developments applied to elderly patients with advanced prostate cancer Cancer Treat Rev 39 2013 578 583
67. Z.I. Malik, A.H. Montazeri, H. Wong, and C. Eswarvee Post docetaxel treatment for castration-resistant prostate cancer (CRPC): does sequencing matter? [abstract e15135] J Clin Oncol 30 Suppl 2012
68. A. Angelergues, D. Maillet, and A. Flechon et al. Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter [abstract 5063] J Clin Oncol 31 Suppl 2013
69. Y. Loriot, D. Bianchini, and E. Ileana et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
70. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807